Cancer stem cells (CSCs) show a self-renewal capacity and differentiation potential that
contribute to tumor progression and therapy resistance. However, the underlying processes …

Liver cancer has become the sixth most diagnosed cancer and the fourth leading cause of
cancer death worldwide. Hepatocellular carcinoma (HCC) is responsible for up to 75–85 …

Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …

Background Sorafenib resistance is a key impediment to successful treatment of patients
with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of …

The prevalence of liver cancer is constantly rising, with increasing incidence and mortality in
Europe and the USA in recent decades. Among the different subtypes of liver cancers …

Simple Summary Acquired resistance to molecularly targeted therapies remains a major
challenge in the treatment of cancer. It has been hypothesized that drug-tolerant (or …

The liver has strong innate immunity to counteract pathogens from the gastrointestinal tract.
During the development of liver cancer, which is typically driven by chronic inflammation, the …

Cancer with a complex pathological process is a major disease to human welfare. Due to
the imbalance between oxygen (O2) supply and consumption, hypoxia is a natural …

Bevacizumab plays an important role in the first and second line treatment for metastatic
colorectal cancer (CRC). And induction of hypoxia and the tumors response to it plays an …

Objective We aimed to elucidate the mutual regulation mechanism of ubiquitin-specific
protease 22 (USP22) and hypoxia inducible factor-1α (HIF1α), and the mechanism they …